Traditional Chinese Medicines (TCMs) for molecular targeted therapies of tumours

Current Drug Discovery Technologies

Volumn 7, Issue 1, 2010, Pages 37-45

  Youns, Mahmoud ^a,b   Hoheisel, Jörg D ^c   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Ein Helwan   (Egypt)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Arsenic trioxide; Artesunate; Berberine; Cantharidin; Curcumin; TCM; Tumour

Indexed keywords

ARSENIC TRIOXIDE; ARTEMISININ; ARTESUNATE; BERBERINE; CANTHARIDIN; CURCUMIN; NATURAL PRODUCT;

ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CHEMICAL STRUCTURE; CHINESE MEDICINE; DRUG ACTIVITY; DRUG TARGETING; HUMAN; MALARIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARSENICALS; ARTEMISININS; BERBERINE; BIOLOGICAL PRODUCTS; CANTHARIDIN; COMPLEMENTARY THERAPIES; CURCUMIN; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, CHINESE HERBAL; HUMANS; MEDICINE, CHINESE TRADITIONAL; MODELS, BIOLOGICAL; NEOPLASMS; OXIDES;

EID: 77951748113     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016310791162730     Document Type: Review

References (123)

1. Avedisian CT, Cavicchi RE, McEuen PL, Zhou X. Nanoparticles for cancer treatment: Role of heat transfer. Ann N Y Acad Sci 2009; 1161: 62-73.
2. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458: 719-724
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA, Cancer. J Clin 2009.
4. Widakowich C, de Azambuja E, Gil T, et al. Molecular targeted therapies in breast cancer: Where are we now? Int J Biochem Cell Biol 2007; 39: 1375-1387
5. Chabner BA, Roberts TG, Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5: 65-72.
6. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346: 683-693 (Pubitemid 34815874)
7. Allgayer H, Fulda S. An introduction to molecular targeted therapy of cancer. Adv Med Sci 2008; 53: 130-138
8. Festuccia C, Angelucci A, Gravina GL, et al. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 2005; 93: 964-975
9. Green JR. Antitumor effects of bisphosphonates. Cancer 2003; 97: 840-847
10. Green JR. Bisphosphonates: Preclinical review. Oncologist 2004; 9(Suppl 4): 3-13.
11. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000; 88: 2961-2978 (Pubitemid 30413179)
12. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 2007; 70: 461-477
13. Efferth T, Li PC, Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007; 13: 353-361 (Pubitemid 47126989)
14. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998; 83: 777-782 (Pubitemid 28387704)
15. Boon H, Brown JB, Gavin A, Kennard MA, Stewart M. Breast cancer survivors' perceptions of complementary/alternative medicine (CAM): Making the decision to use or not to use. Qual Health Res 1999; 9: 639-653
16. Xu W, Towers AD, Li P, Collet JP. Traditional Chinese medicine in cancer care: Perspectives and experiences of patients and professionals in China. Eur J Cancer Care (Engl) 2006; 15: 397-403. (Pubitemid 44359404)
17. Efferth T, Fu YJ, Zu YG, Schwarz G, Konkimalla VS, Wink M. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr Med Chem 2007; 14: 2024-2032 (Pubitemid 47578160)
18. Macek C. East meets West to balance immunologic yin and yang. JAMA 1984; 251: 433-5, 9.
19. Wong R, Sagar CM, Sagar SM. Integration of Chinese medicine into supportive cancer care: a modern role for an ancient tradition. Cancer Treat Rev 2001; 27: 235-246 (Pubitemid 32851176)
20. Pu CY, Lan VM, Lan CF, Lang HC. The determinants of traditional Chinese medicine and acupuncture utilization for cancer patients with simultaneous conventional treatment. Eur J Cancer Care (Engl) 2008; 17: 340-349
21. Yin J, Zhang H, Ye J. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008; 8: 99-111.
22. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985; 228: 1049-1055
23. Price RN. Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 2000; 9: 1815-1827
24. Fishwick J, McLean WG, Edwards G, Ward SA. The toxicity of artemisinin and related compounds on neuronal and glial cells in culture. Chem Biol Interact 1995; 96: 263-271
25. Hien TT, Phu NH, Mai NT, et al. An open randomized comparison of intravenous and intramuscular artesunate in severe falciparum malaria. Trans R Soc Trop Med Hyg 1992; 86: 584-585
26. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341: 603-608
27. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001; 18: 767-773
28. Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 2001; 70: 49-56. (Pubitemid 33130042)
29. Dell'Eva R, Pfeffer U, Vene R, et al. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 2004; 68: 2359-2366
30. Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 2003; 48: 231-236 (Pubitemid 36818928)
31. Li LN, Zhang HD, Yuan SJ, Tian ZY, Wang L, Sun ZX. Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int J Cancer 2007; 121: 1360-1365 (Pubitemid 47293806)
32. Efferth T, Sauerbrey A, Olbrich A, et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003; 64: 382-394 (Pubitemid 36910002)
33. Efferth T, Olbrich A, Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem Pharmacol 2002; 64: 617-623
34. Efferth T, Giaisi M, Merling A, Krammer PH, Li-Weber M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One 2007; 2: e693. (Pubitemid 351325407)
35. Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 2007; 28: 1045-1056 (Pubitemid 47020494)
36. Konkimalla VB, Blunder M, Korn B, et al. Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. Nitric Oxide 2008; 19: 184-191
37. Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res 2008; 68: 4347-4351
38. Youns M, Efferth T, Reichling J, Fellenberg K, Bauer A, Hoheisel JD. Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. Biochem Pharmacol 2009; 78: 273-283
39. Takase H, Yamamoto K, Ito K, Yumioka E. Pharmacological studies on antidiarrheal effects of berberine and geranii herba. Nippon Yakurigaku Zasshi 1993; 102: 101-112 (Pubitemid 23278238)
40. Huang WM, Wu ZD, Gan YQ. Effects of berberine on ischemic ventricular arrhythmia. Zhonghua Xin Xue Guan Bing Za Zhi 1989; 17: 300-1, 19.
41. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 2004; 203: 127-137
42. Hoshi A, Ikekawa T, Ikeda Y, Shirakawa S, Iigo M. Antitumor activity of berberrubine derivatives. Gann 1976; 67: 321-325
43. Choi MS, Oh JH, Kim SM, et al. Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells. Int J Oncol 2009; 34: 1221-1230
44. Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S, Fujiwara H. Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells. J Ethnopharmacol 1999; 66: 227-233 (Pubitemid 29307925)
45. Lin JG, Chung JG, Wu LT, Chen GW, Chang HL, Wang TF. Effects of berberine on arylamine N-acetyltransferase activity in human colon tumor cells. Am J Chin Med 1999; 27: 265-275
46. Mazzini S, Bellucci MC, Mondelli R. Mode of binding of the cytotoxic alkaloid berberine with the double helix oligonucleotide d(AAGAATTCTT)(2). Bioorg Med Chem 2003; 11: 505-514
47. Qin Y, Pang JY, Chen WH, Cai Z, Jiang ZH. Synthesis, DNA-binding affinities, and binding mode of berberine dimers. Bioorg Med Chem 2006; 14: 25-32.
48. Tse WC, Boger DL. A fluorescent intercalator displacement assay for establishing DNA binding selectivity and affinity. Acc Chem Res 2004; 37: 61-69
49. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-375 (Pubitemid 19172974)
50. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer 1997; 80: 1529-1537
51. Liotta LA. Tumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986; 46: 1-7.
52. Oka T, Ishida T, Nishino T, Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res 1991; 51: 3522-3525
53. Lee SJ, Sakurai H, Oshima K, Kim SH, Saiki I. Anti-metastatic and anti-angiogenic activities of a new matrix metalloproteinase inhibitor, TN-6b. Eur J Cancer 2003; 39: 1632-1641 (Pubitemid 36829205)
54. Naglich JG, Jure-Kunkel M, Gupta E, et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res 2001; 61: 8480-8485 (Pubitemid 33131128)
55. Kim S, Choi JH, Kim JB, et al. Berberine suppresses TNF-alpha-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells. Molecules 2008; 13: 2975-2985
56. Ho YT, Yang JS, Li TC, et al. Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-kappaB, u-PA and MMP-2 and -9. Cancer Lett 2009; 279: 155-162
57. Clarke PR, Hoffmann I, Draetta G, Karsenti E. Dephosphorylation of cdc25-C by a type-2A protein phosphatase: Specific regulation during the cell cycle in Xenopus egg extracts. Mol Biol Cell 1993; 4: 397-411. (Pubitemid 23122127)
58. Sontag E, Fedorov S, Kamibayashi C, Robbins D, Cobb M, Mumby M. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 1993; 75: 887-897 (Pubitemid 24014546)
59. Chen YN, Chen JC, Yin SC, et al. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer 2002; 100: 158-165
60. Kok SH, Cheng SJ, Hong CY, et al. Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio. Cancer Lett 2005; 217: 43-52. (Pubitemid 39642865)
61. Yi SN, Wass J, Vincent P, Iland H. Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res 1991; 15: 883-886
62. Wang GS. Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 1989; 26: 147-162
63. Liu XH, Blazsek I, Comisso M, et al. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur J Cancer 1995; 31A: 953-963
64. Efferth T, Rauh R, Kahl S, et al. Molecular modes of action of cantharidin in tumor cells. Biochem Pharmacol 2005; 69: 811-818 (Pubitemid 40248623)
65. Li YM, Casida JE. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc Natl Acad Sci USA 1992; 89: 11867-11870
66. McCluskey A, Ackland SP, Gardiner E, Walkom CC, Sakoff JA. The inhibition of protein phosphatases 1 and 2A: A new target for rational anti-cancer drug design? Anticancer Drug Des 2001; 16: 291-303.
67. Wera S, Hemmings BA. Serine/threonine protein phosphatases. Biochem J 1995; 311( Pt 1): 17-29.
68. Kok SH, Hong CY, Kuo MY, et al. Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol 2003; 39: 19-26.
69. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58. (Pubitemid 37328807)
70. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537-7552
71. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-15670 (Pubitemid 29018757)
72. Zheng LH, Bao YL, Wu Y, Yu CL, Meng X, Li YX. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer Lett 2008; 272: 102-109
73. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340-7358
74. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20. (Pubitemid 37046923)
75. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115 (Pubitemid 29077388)
76. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99: 1885-1893 (Pubitemid 34525465)
77. Sagawa M, Nakazato T, Uchida H, Ikeda Y, Kizaki M. Cantharidin induces apoptosis of human multiple myeloma cells via inhibition of the JAK/STAT pathway. Cancer Sci 2008; 99: 1820-1826
78. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903
79. Klaassen CD. Heavy metals and heavy-metal antagonists. Goodman and Gilman's The Pharmacological basis of therapeutics. New York 1996, pp. 1649-1672
80. Haller JS. Therapeutic mule: The use of arsenic in the nineteenth century materia medica. Pharm Hist 1975; 17: 87-100.
81. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88: 1052-1061
82. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860 (Pubitemid 32880064)
83. Huang XJ, Wiernik PH, Klein RS, Gallagher RE. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med Oncol 1999; 16: 58-64. (Pubitemid 29238383)
84. Anderson KC, Boise LH, Louie R, Waxman S. Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 2002; 8: 12-25.
85. Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002; 1: 851-860
86. Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003; 101: 4078-4087 (Pubitemid 36857889)
87. Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530 (Pubitemid 30658486)
88. Efferth T. Microarray-based prediction of cytotoxicity of tumor cells to cantharidin. Oncol Rep 2005; 13: 459-463 (Pubitemid 40248623)
89. Ramirez P, Del Razo LM, Gutierrez-Ruiz MC, Gonsebatt ME. Arsenite induces DNA-protein crosslinks and cytokeratin expression in the WRL-68 human hepatic cell line. Carcinogenesis 2000; 21: 701-706 (Pubitemid 30214027)
90. Yih LH, Peck K, Lee TC. Changes in gene expression profiles of human fibroblasts in response to sodium arsenite treatment. Carcinogenesis 2002; 23: 867-876 (Pubitemid 34567528)
91. Bae DS, Handa RJ, Yang RS, Campain JA. Gene expression patterns as potential molecular biomarkers for malignant transformation in human keratinocytes treated with MNNG, arsenic, or a metal mixture. Toxicol Sci 2003; 74: 32-42.
92. Lin S, Del Razo LM, Styblo M, Wang C, Cullen WR, Thomas DJ. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol 2001; 14: 305-311 (Pubitemid 32238491)
93. Ma X, Hu J, Lindner DJ, Kalvakolanu DV. Mutational analysis of human thioredoxin reductase 1. Effects on p53-mediated gene expression and interferon and retinoic acid-induced cell death. J Biol Chem 2002; 277: 22460-22468 (Pubitemid 34967218)
94. Efferth T, Kaina B. Pharmacogenomics of Biotic and Abiotic Natural Products Derived from Traditional Chinese Medicine for Cancer Therapy. In: Maria C, Carpinella MR, Eds. Novel Therapeutic Agents from Plants. USA: Science Publishers 2009.
95. Anestal K, Arner ES. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 2003; 278: 15966-15972 (Pubitemid 36799715)
96. Huang MT, Wang ZY, Georgiadis CA, Laskin JD, Conney AH. Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene. Carcinogenesis 1992; 13: 2183-2186
97. Conney AH, Lysz T, Ferraro T, et al. Inhibitory effect of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin. Adv Enzyme Regul 1991; 31: 385-396
98. Huang MT, Smart RC, Wong CQ, Conney AH. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1988; 48: 5941-5946
99. Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 2008; 76: 1340-1351
100. 2+ uniporter, inhibits curcumin-induced apoptosis via the prevention of intracellular Ca2+ depletion and cytochrome c release. Biochem Biophys Res Commun 2003; 303: 1073-1079
101. Pal S, Choudhuri T, Chattopadhyay S, et al. Mechanisms of curcumin-induced apoptosis of Ehrlich's ascites carcinoma cells. Biochem Biophys Res Commun 2001; 288: 658-665 (Pubitemid 33030080)
102. Shankar S, Chen Q, Sarva K, Siddiqui I, Srivastava RK. Curcumin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of apoptosis, migration and angiogenesis. J Mol Signal 2007; 2: 10. (Pubitemid 350162838)
103. Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 3′-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol 2007; 30: 905-918
104. Woo JH, Kim YH, Choi YJ, et al. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003; 24: 1199-1208
105. 2+ and the activation of caspase-3. Anticancer Res 2006; 26: 4379-4389
106. Tan TW, Tsai HR, Lu HF, et al. Curcumin-induced cell cycle arrest and apoptosis in human acute promyelocytic leukemia HL-60 cells via MMP changes and caspase-3 activation. Anticancer Res 2006; 26: 4361-4371
107. Yoshino M, Haneda M, Naruse M, et al. Prooxidant activity of curcumin: copper-dependent formation of 8-hydroxy-2′-deoxyguanosine in DNA and induction of apoptotic cell death. Toxicol In vitro 2004; 18: 783-789 (Pubitemid 39311889)
108. Syng-Ai C, Kumari AL, Khar A. Effect of curcumin on normal and tumor cells: Role of glutathione and bcl-2. Mol Cancer Ther 2004; 3: 1101-1108 (Pubitemid 39295007)
109. Moussavi M, Assi K, Gomez-Munoz A, Salh B. Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 2006; 27: 1636-1644 (Pubitemid 44288053)
110. Moos PJ, Edes K, Mullally JE, Fitzpatrick FA. Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 2004; 25: 1611-1617 (Pubitemid 39214303)
111. Song G, Mao YB, Cai QF, Yao LM, Ouyang GL, Bao SD. Curcumin induces human HT-29 colon adenocarcinoma cell apoptosis by activating p53 and regulating apoptosis-related protein expression. Braz J Med Biol Res 2005; 38: 1791-1798 (Pubitemid 43078608)
112. Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 2002; 512: 334-340 (Pubitemid 34164505)
113. Bush JA, Cheung KJ, Jr., Li G. Curcumin induces apoptosis in human melanoma cells through a FAS receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001; 271: 305-314 (Pubitemid 33141212)
114. Moragoda L, Jaszewski R, Majumdar AP. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res 2001; 21: 873-878 (Pubitemid 32494183)
115. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001; 20: 7597-7609 (Pubitemid 33111860)
116. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: Its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 2002; 23: 143-150
117. Bielak-Mijewska A, Piwocka K, Magalska A, Sikora E. Pglycoprotein expression does not change the apoptotic pathway induced by curcumin in HL-60 cells. Cancer Chemother Pharmacol 2004; 53: 179-185 (Pubitemid 38186998)
118. Jana NR, Dikshit P, Goswami A, Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 2004; 279: 11680-11685 (Pubitemid 38401671)
119. 2+. J Biol Chem 2001; 276: 46905-46911
120. Bharti AC, Shishodia S, Reuben JM, et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103: 3175-3184
121. Marin YE, Wall BA, Wang S, et al. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res 2007; 17: 274-283
122. Lin SS, Lai KC, Hsu SC, et al. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett 2009.
123. Li J, Wang Y, Yang C, et al. PEGylated Curcumin Conjugate Inhibits Pancreatic Cancer Cell Growth through Inactivation of Jab1. Mol Pharmacol 2009; 76(1): 81-90..